Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16, Activation of the DNA Damage Response Pathway
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The molecular hallmarks of inflammation-mediated lung carcinogenesis have not been fully clarified, mainly due to the scarcity of appropriate animal models. We have used a silica-induced multistep lung carcinogenesis model driven by chronic inflammation to study the evolution of molecular markers and genetic alterations. We analyzed markers of DNA damage response (DDR), proliferative stress, and telomeric stress: gamma-H2AX, p16, p53, and TERT. Lung cancer-related epigenetic and genetic alterations, including promoter hypermethylation status of p16(CDKN2A), APC, CDH13, Rassf1, and Nore1A, as well as mutations of Tp53, epidermal growth factor receptor, K-ras, N-ras, and c-H-ras, have been also studied. Our results showed DDR pathway activation in preneoplastic lesions, in association with inducible nitric oxide synthase and p53 induction. p16 was also induced in early tumorigenic progression and was inactivated in bronchiolar dysplasias and tumors. Remarkably, lack of mutations of Ras and epidermal growth factor receptor, and a very low frequency of Tp53 mutations suggest that they are not required for tumorigenesis in this model. In contrast, epigenetic alterations in p16(CDKN2A), CDH13, and APC, but not in Rassf1 and Nore1A, were clearly observed. These data suggest the existence of a specific molecular signature of inflammation-driven lung carcinogenesis that shares some, but not all, of the molecular landmarks of chemically induced lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“preneoplastic lesions either by DNA replication stress or by oncogenic stress [20,21,54].”
BackgroundActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · cited 2×
“preneoplastic lesions either by DNA replication stress or by oncogenic stress [20,21,54].”
BackgroundOncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
ROS, stress‐activated kinases and stress signaling in cancer
Benhar, M., Engelberg, D., & Levitzki, A. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf094 · Cited by 600 · cited 1×
“signaling pathways, chemokines and cytokines (TNF-a, IL-1, IL-6, and IL-8), growth and angiogenic factors (PDGF, TGF-b, and EGF), proteolytic enzymes, and cytotoxic agents such as ROS and nitric oxide (NO) [4,8,9].”
BackgroundTelomerase modulates expression of growth-controlling genes and enhances cell proliferation
Smith, L. L., Coller, H. A., & Roberts, J. M. (2003) · Nature Cell Biology · doi:10.1038/ncb985 · Cited by 438
Yang, H., Bocchetta, M., Kroczynska, B., Elmishad, A. G., Chen, Y., Liu, Z., Bubici, C., Mossman, B. T., Pass, H. I., Testa, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604008103 · Cited by 322
p16 INK4A Participates in a G 1 Arrest Checkpoint in Response to DNA Damage
Shapiro, G. I., Edwards, C. D., Ewen, M. E., & Rollins, B. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.378 · Cited by 165
Evolving views of telomerase and cancer
Blasco, M. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00085-0 · Cited by 123
Cited by
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials
Singh, N., Manshian, B., Jenkins, G. J. S., Griffiths, S. M., Williams, P. M., Maffeis, T. G. G., Wright, C. J., & Doak, S. H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.04.009 · Cited by 1,184
Tammemagi, C. M., Pinsky, P. F., Caporaso, N. E., Kvale, P. A., Hocking, W. G., Church, T. R., Riley, T. L., Commins, J., Oken, M. M., Berg, C. D., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr173 · Cited by 310
Desaulniers, D., Xiao, G.-H., Lian, H., Feng, Y.-L., Zhu, J., Nakai, J., & Bowers, W. J. (2009) · International Journal of Toxicology · doi:10.1177/1091581809337918 · Cited by 114
“In fact, Blanco et al showed increases in methylation of CpG sites occurring only downstream of the transcriptional start site in lung tumors (a DNA segment not investigated here).(79) Perhaps the small increase in methylation at position 23 (the position closest to the transcriptional start site in Figure 4) is part…”
BackgroundResultRittinghausen, S., Bellmann, B., Creutzenberg, O., Ernst, H., Kolling, A., Mangelsdorf, I., Kellner, R., Beneke, S., & Ziemann, C. (2013) · Toxicology · doi:10.1016/j.tox.2012.11.007 · Cited by 28
Metadata
- Authors
- Blanco, D., Vicent, S., Fraga, M. F., Fernandez-Garcia, I., Freire, J., Lujambio, A., Esteller, M., Ortiz-de-Solorzano, C., Pio, R., Lecanda, F., & Montuenga, L. M.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 9
- Issue
- 10
- Pages
- 840-IN12
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2029921049
- Cited by
- 92
- References
- 8
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.